1.
Ann Hematol
; 102(6): 1599-1600, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37099080
2.
Leuk Res Rep
; 19: 100369, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37213444
RESUMO
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epstein-Barr virus (EBV) seropositivity and reactivation can be a major risk factor for PTLD. A few PTLDs could be EBV negative. There are a very limited number of PTLD cases following HSCT in patients with AML. We present a differential diagnosis of cytopenias after allo-HSCT. This is the first report of an AML patient developing bone marrow EBV-negative PTLD relatively late in their post-transplant course.
3.
Indian J Hematol Blood Transfus
; 40(3): 527-530, 2024 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-39011240